ConductScience.org, home
Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational)
API referenceFor AI assistants

Trial · NCT02181738

Participant flow20

How many started, completed or left each group, period by period.

1 to 20 of 20

Download this page as JSON
PeriodMilestoneGroupParticipantsUnits counted
Overall StudySTARTEDCohort A: Post-Transplant, Never Taken Brentuximab Vedotin63
Overall StudySTARTEDCohort B: Post Transplant, Brentuximab Vedotin Taken Post-Autologous Stem Cell Transplant80
Overall StudySTARTEDCohort C: Post Transplant, Brentuximab Vedotin Taken Pre-and/or Post-Autologous Stem Cell Transplant100
Overall StudySTARTEDCohort D: Newly Diagnosed, Previously Untreated Advanced Stage cHL (Stage IIB, III and IV)51
Overall StudyN-AVD Combination Therapy PhaseCohort A: Post-Transplant, Never Taken Brentuximab Vedotin0
Overall StudyN-AVD Combination Therapy PhaseCohort B: Post Transplant, Brentuximab Vedotin Taken Post-Autologous Stem Cell Transplant0
Overall StudyN-AVD Combination Therapy PhaseCohort C: Post Transplant, Brentuximab Vedotin Taken Pre-and/or Post-Autologous Stem Cell Transplant0
Overall StudyN-AVD Combination Therapy PhaseCohort D: Newly Diagnosed, Previously Untreated Advanced Stage cHL (Stage IIB, III and IV)49
Overall StudyN-AVD Combination Therapy PhaseCohort A: Post-Transplant, Never Taken Brentuximab Vedotin0
Overall StudyN-AVD Combination Therapy PhaseCohort B: Post Transplant, Brentuximab Vedotin Taken Post-Autologous Stem Cell Transplant0
Overall StudyN-AVD Combination Therapy PhaseCohort C: Post Transplant, Brentuximab Vedotin Taken Pre-and/or Post-Autologous Stem Cell Transplant0
Overall StudyN-AVD Combination Therapy PhaseCohort D: Newly Diagnosed, Previously Untreated Advanced Stage cHL (Stage IIB, III and IV)1
Overall StudyCOMPLETEDCohort A: Post-Transplant, Never Taken Brentuximab Vedotin0
Overall StudyCOMPLETEDCohort B: Post Transplant, Brentuximab Vedotin Taken Post-Autologous Stem Cell Transplant0
Overall StudyCOMPLETEDCohort C: Post Transplant, Brentuximab Vedotin Taken Pre-and/or Post-Autologous Stem Cell Transplant13
Overall StudyCOMPLETEDCohort D: Newly Diagnosed, Previously Untreated Advanced Stage cHL (Stage IIB, III and IV)45
Overall StudyNOT COMPLETEDCohort A: Post-Transplant, Never Taken Brentuximab Vedotin63
Overall StudyNOT COMPLETEDCohort B: Post Transplant, Brentuximab Vedotin Taken Post-Autologous Stem Cell Transplant80
Overall StudyNOT COMPLETEDCohort C: Post Transplant, Brentuximab Vedotin Taken Pre-and/or Post-Autologous Stem Cell Transplant87
Overall StudyNOT COMPLETEDCohort D: Newly Diagnosed, Previously Untreated Advanced Stage cHL (Stage IIB, III and IV)6

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02181738/flow

API referenceFor AI assistants